Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III neoadjuvant Darleukin + Fibromun versus surgery alone in resectable stage IIIB/IIIC melanoma
2015-002549-72Phase 3Active
- Sponsor
- Philogen
- Start
- Jul 2015
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of darleukin and onfekafusp alfa in melanoma (2 arms), sponsored by Philogen. Primary endpoint: Recurrence-free survival. Started Jul 2015; status: active.
02
Drugs
darleukinonfekafusp alfa
03
Conditions
melanoma
Beyond the preview
Go deeper on 2015-002549-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002549-72.